HomeCompareEIGRQ vs STAG

EIGRQ vs STAG: Dividend Comparison 2026

EIGRQ yields 23.53% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGRQ wins by $72.1K in total portfolio value
10 years
EIGRQ
EIGRQ
● Live price
23.53%
Share price
$8.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.5K
Annual income
$9,663.72
Full EIGRQ calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — EIGRQ vs STAG

📍 EIGRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRQSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGRQ + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGRQ pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGRQ
Annual income on $10K today (after 15% tax)
$2,000.00/yr
After 10yr DRIP, annual income (after tax)
$8,214.16/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, EIGRQ beats the other by $7,820.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGRQ + STAG for your $10,000?

EIGRQ: 50%STAG: 50%
100% STAG50/50100% EIGRQ
Portfolio after 10yr
$54.4K
Annual income
$5,063.21/yr
Blended yield
9.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

EIGRQ
No analyst data
Altman Z
-24.3
Piotroski
4/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGRQ buys
0
STAG buys
0
No recent congressional trades found for EIGRQ or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRQSTAG
Forward yield23.53%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$90.5K$18.3K
Annual income after 10y$9,663.72$462.70
Total dividends collected$55.7K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: EIGRQ vs STAG ($10,000, DRIP)

YearEIGRQ PortfolioEIGRQ Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$13,053$2,352.94$10,665$345.38+$2.4KEIGRQ
2$16,837$2,870.36$11,365$358.01+$5.5KEIGRQ
3$21,476$3,460.26$12,099$370.76+$9.4KEIGRQ
4$27,104$4,124.87$12,870$383.63+$14.2KEIGRQ
5$33,867$4,865.30$13,678$396.60+$20.2KEIGRQ
6$41,919$5,681.51$14,526$409.67+$27.4KEIGRQ
7$51,425$6,572.30$15,413$422.82+$36.0KEIGRQ
8$62,561$7,535.33$16,343$436.05+$46.2KEIGRQ
9$75,507$8,567.24$17,315$449.35+$58.2KEIGRQ
10$90,456$9,663.72$18,332$462.70+$72.1KEIGRQ

EIGRQ vs STAG: Complete Analysis 2026

EIGRQStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Full EIGRQ Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this EIGRQ vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGRQ vs SCHDEIGRQ vs JEPIEIGRQ vs OEIGRQ vs KOEIGRQ vs MAINEIGRQ vs PLDEIGRQ vs EQREIGRQ vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.